Compare LND & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | OMER |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.6M | 628.9M |
| IPO Year | 2006 | 2009 |
| Metric | LND | OMER |
|---|---|---|
| Price | $3.75 | $10.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.50 |
| AVG Volume (30 Days) | 54.9K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,991,256.00 | N/A |
| Revenue This Year | $40.80 | N/A |
| Revenue Next Year | $5.24 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.47 | $2.95 |
| 52 Week High | $4.03 | $13.60 |
| Indicator | LND | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 59.20 |
| Support Level | $3.61 | $9.31 |
| Resistance Level | $3.75 | $11.71 |
| Average True Range (ATR) | 0.09 | 0.67 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 86.21 | 51.11 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.